TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

11291	Companies
250917	Keywords
179768	Articles
136755	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 08/27/2024 at 07:30, 2 years 2 months ago

Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
Transgene announces preclinical proof-of-concept data of oncolytic virus TG6050 published in JITC, showcasing tumor regression and immune remodeling capabilities without systemic toxicity. TG6050 progressing in Phase I trial for NSCLC

Phase I Trial Transgene Oncolytic Virus TG6050 JITC Publication
BRIEF

published on 07/30/2024 at 21:06, 2 years 3 months ago

Transgene consolidates its balance sheet thanks to the conversion of part of the advance into shares

Biotechnology Immunotherapy Increase In Capital Transgene Mérieux Institute
BRIEF

published on 06/03/2024 at 07:35, 2 years 5 months ago

Transgene includes the first patient in Phase II of the study of its TG4050 vaccine against head and neck cancers

Head And Neck Cancer Transgene TG4050 Phase II Therapeutic Vaccine
PRESS RELEASE

published on 06/03/2024 at 07:30, 2 years 5 months ago

Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025

Phase II Trial Head And Neck Cancer Cancer Vaccine Transgene TG4050
BRIEF

published on 05/14/2024 at 17:50, 2 years 5 months ago

Transgene Announces Positive Q1 2024 Update and Future Clinical Milestones

Clinical Trials Financial Update Cancer Immunotherapy Transgene TG4050
PRESS RELEASE

published on 05/14/2024 at 17:45, 2 years 5 months ago

Transgene provides business and financial update for Q1 2024
Transgene provides business and financial update for Q1 2024, including promising Phase I data on TG4050 and upcoming clinical data expectations on TG4001, TG6050, and BT-001 in H2 2024

Clinical Data Q1 2024 Financial Update Transgene TG4050

Accesswire

Published on 11/06/2026 at 13:00, 1 hour 40 minutes ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 hours 10 minutes ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 hours 10 minutes ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 4 hours 40 minutes ago

Mongolia Tax Audit
Published on 11/06/2026 at 05:15, 9 hours 25 minutes ago

Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins

View all ACCESSWIRE

EQS Group

Published on 11/06/2026 at 14:38, 2 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc
Published on 11/06/2026 at 14:37, 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 11/06/2026 at 14:36, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 11/06/2026 at 14:36, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Vesuvius plc
Published on 11/06/2026 at 14:35, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: easyJet plc

Les Echos

Published on 11/06/2026 at 11:05, 3 hours 35 minutes ago

voting rights
Published on 11/05/2026 at 18:21, 20 hours 18 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:50, 20 hours 50 minutes ago

NRJ GROUP - Financial information Q3 2026
Published on 11/05/2026 at 17:45, 20 hours 55 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 21 hours 11 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082

View all LES ECHOS COMFI WIRE